Document is current
Any future updates will be listed below
-
Authors
Puig-Saus, Cristina https://orcid.org/0000-0002-3014-3649
Sennino, Barbara
Peng, Songming
Wang, Clifford L.
Pan, Zheng
Yuen, Benjamin
Purandare, Bhamini
An, Duo
Quach, Boi B.
Nguyen, Diana
Xia, Huiming https://orcid.org/0000-0003-2571-1880
Jilani, Sameeha
Shao, Kevin
McHugh, Claire
Greer, John
Peabody, Phillip
Nayak, Saparya
Hoover, Jonathan https://orcid.org/0000-0002-2893-4425
Said, Sara
Jacoby, Kyle
Dalmas, Olivier
Foy, Susan P.
Conroy, Andrew
Yi, Michael C.
Shieh, Christine
Lu, William
Heeringa, Katharine
Ma, Yan
Chizari, Shahab https://orcid.org/0000-0002-5659-1140
Pilling, Melissa J.
Ting, Marc
Tunuguntla, Ramya
Sandoval, Salemiz
Moot, Robert
Hunter, Theresa
Zhao, Sidi
Saco, Justin D.
Perez-Garcilazo, Ivan
Medina, Egmidio
Vega-Crespo, Agustin
Baselga-Carretero, Ignacio
Abril-Rodriguez, Gabriel
Cherry, Grace
Wong, Deborah J.
Hundal, Jasreet
Chmielowski, Bartosz https://orcid.org/0000-0002-2374-3320
Speiser, Daniel E.
Bethune, Michael T.
Bao, Xiaoyan R.
Gros, Alena https://orcid.org/0000-0002-1207-1880
Griffith, Obi L. https://orcid.org/0000-0002-0843-4271
Griffith, Malachi https://orcid.org/0000-0002-6388-446X
Heath, James R. https://orcid.org/0000-0001-5356-4385
Franzusoff, Alex
Mandl, Stefanie J.
Ribas, Antoni https://orcid.org/0000-0003-3669-8458
- License Information
-
More Information
Article History
Received: 29 May 2020
Accepted: 2 February 2023
First Online: 8 March 2023
Competing interests
: B.S., S.P., C.L.W., Z.P., B.P., A.C., D.A., B.B.Q., B.Y., K.J., O.D., D.N., K.S., J.G., J. Hoover., S. Said., W.L., C.S., K.H., Y.M., S.C., M.J.P., M.T., R.T., C.M., P.P., S.N., S.P.F., T.H., M.Y., S. Sandoval., R.M., X.R.B., M.T.B., A.F. and S.J.M. are current or former employees of PACT Pharma, and hold stock in the company. S.P., M.T.B., J.R.H. and A.R. are co-founders of PACT Pharma, and hold founder stock. J.R.H. and A.R. are members of the scientific advisory board of PACT Pharma. J.R.H. and A.R. are members of the board of directors of PACT Pharma. A.R. has received honoraria from consulting with Amgen, Bristol-Myers Squibb, Chugai, Dynavax, Genentech, Merck, Nektar, Novartis, Roche and Sanofi; is or has been a member of the scientific advisory board and holds stock in Advaxis, Arcus Biosciences, Bioncotech Therapeutics, Compugen, CytomX, Five Prime, RAPT, ImaginAb, Isoplexis, Kite-Gilead, Lutris Pharma, Merus, Rgenix and Tango Therapeutics. C.P.-S. and A.R. are listed as inventors on and receive licensing revenue from a patent application covering the use of non-viral gene editing of T cells that was licensed by The Regents of the University of California to Arsenal Bio (South San Francisco; WO2019084552A1, application filed by The Regents Of The University Of California); the methods and technology described therein were not used in the experiments performed herein. A.G. reports receiving funding from Novartis, VCN Biosciences and Merck KGaA, has received speaker honoraria from Roche, and has consulted for Achilles Therapeutics, Neon Therapeutics, PACT Pharma and Oxford Immunotherapy. Patent applications have been filed on aspects of the described work by PACT Pharma, entitled ‘Peptide-MHC comPACTs’, ‘Compositions and Methods For Identification of Antigen Specific T Cells’ and ‘Primary Cell Gene Editing’. The other authors declare no competing interests.
